Meeting
2020 Genitourinary Cancers Symposium
Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy (RC).
Authors
Laura Marandino
Department of Oncology, University of Turin, Candiolo Cancer Institute-FPO-IRCCS, Candiolo (TO), Italy
Laura Marandino , Antonella Capozza , Alberto Briganti , Daniele Raggi , Elena Farè , Filippo Pederzoli , Andrea Gallina , Marco Bandini , Umberto Capitanio , Marco Bianchi , Giorgio Gandaglia , Nicola Fossati , Patrizia Giannatempo , Ettore Seregni , Andrea Salonia , Francesco Montorsi , Alessandra Alessi , Andrea Necchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Imaging
Clinical Trial Registration Number
NCT02736266
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 445)
Abstract #
445
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.
First Author: Filippo Pederzoli
Poster
2020 Genitourinary Cancers Symposium
Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.
First Author: Matt D. Galsky
Poster
2023 ASCO Annual Meeting
Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.
First Author: Andrea Necchi
Poster
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.
First Author: Kyle M Rose